Clinical Trial Update: Pemigatinib + Afatinib in Advanced Refractory Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating the combination of pemigatinib and afatinib in advanced, unresectable, or metastatic solid tumors is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• Gilotrif (Afatinib)
• Pemazyre (pemigatinib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Advanced Solid Tumor, Unresectable Solid Tumor | Phase 1 | Status: RECRUITING